The Study of Tadalafil and Tamsulosin as Monotherapy for Lower Urinary Tract Symptoms Due to Benign Hyperplasia of Prostate.

Corresponding Author:
Dr. Sudhakaran Selvaraj,
No. 1, Meeyanna Kadir Street,
Vandavasi-604408,
Tamilnadu, India.
E-mail: tarugiffy@gmail.com

ABSTRACT

BACKGROUND

BPH is the most common benign tumour in men and its incidence increases with age. BPH is a histological diagnosis which is identified by non-malignant hyperplasia of prostatic tissue due to smooth cell and epithelial cell proliferation. Although the current medical therapy, alpha 1 blocker alone or in combination with 5 alpha reductase inhibitors, for BPH-LUTS is effective, it has potential side effects on sexual function like retrograde ejaculation/anejaculation. BPH refers to proliferation of smooth muscle and epithelial cells within the prostate gland mainly involving transitional zone. The aim of this study is to compare Tadalafil and Tamsulosin as monotherapy in the treatment of BPH.

METHODS

We analysed 60 patients of BPH (Benign Prostatic Hyperplasia) with LUTS (Lower Urinary Tract Symptoms) with baseline parameters as International Prostate Symptom Score (IPSS), QMAX (maximum urinary flow velocity), PVR (Post Voidal Residual urine volume), for a period of 6 months. They were divided in to two groups, one group receiving only alpha blockers, other group receiving only PDE -5 inhibitor (Phosphodiesterase type 5 inhibitor/PDE-5I) tadalafil in treatment of LUTS due to BPH. These patients were reviewed at 1-, 3-, 6-month intervals with the above-mentioned parameters.

RESULTS

Of the 60 patients taken up for the study, 30 in each group, only 55 patients completed the study. (27 patients in alpha blockers group and 28 patients in PDE-5 inhibitors group). Both groups were reviewed with mentioned parameters.

CONCLUSIONS

PDE-5 inhibitor (Tadalafil) should be preferred over alpha blockers in treating LUTS (Lower Urinary Tract Symptoms) due to BPH (Benign Prostatic Hyperplasia) as PDE -5 inhibitors are found to be more efficacious than alpha blocker with lesser incidences of side-effects.

KEY WORDS

BPH (Benign Prostatic Hyperplasia), LUTS (Lower Urinary Tract Symptoms), Alpha Blockers, Phosphodiesterase Type 5 Inhibitor, IPSS (International Prostatic Symptom Score), Uroflowmetry, PVR (Post Voidal Residual Urine Volume)